A detailed history of Simon Quick Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Simon Quick Advisors, LLC holds 2,236 shares of VRTX stock, worth $1.01 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
2,236
Previous 2,212 1.08%
Holding current value
$1.01 Million
Previous $1.03 Million 12.45%
% of portfolio
0.05%
Previous 0.07%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 17, 2025

BUY
$396.64 - $516.74 $9,519 - $12,401
24 Added 1.08%
2,236 $900,000
Q3 2024

Oct 15, 2024

BUY
$460.0 - $505.78 $468,280 - $514,884
1,018 Added 85.26%
2,212 $1.03 Million
Q2 2024

Aug 02, 2024

SELL
$392.81 - $485.53 $76,205 - $94,192
-194 Reduced 13.98%
1,194 $559,000
Q1 2024

Apr 19, 2024

BUY
$407.69 - $446.08 $211,183 - $231,069
518 Added 59.54%
1,388 $580,000
Q4 2023

Jan 16, 2024

BUY
$343.0 - $410.68 $10,633 - $12,731
31 Added 3.69%
870 $353,000
Q3 2023

Oct 24, 2023

BUY
$338.18 - $362.46 $53,094 - $56,906
157 Added 23.02%
839 $291,000
Q2 2023

Aug 01, 2023

BUY
$314.42 - $351.91 $214,434 - $240,002
682 New
682 $240,000
Q4 2020

Jan 27, 2021

SELL
$207.01 - $276.09 $22,771 - $30,369
-110 Closed
0 $0
Q3 2020

Oct 26, 2020

SELL
$255.65 - $303.1 $2,300 - $2,727
-9 Reduced 7.56%
110 $30,000
Q1 2020

Apr 09, 2020

BUY
$199.77 - $247.81 $5,793 - $7,186
29 Added 32.22%
119 $28,000
Q4 2019

Jan 06, 2020

BUY
$166.71 - $223.91 $12,169 - $16,345
73 Added 429.41%
90 $20,000
Q3 2019

Oct 16, 2019

BUY
$166.23 - $187.09 $2,160 - $2,432
13 Added 325.0%
17 $3,000
Q2 2019

Aug 05, 2019

BUY
$164.61 - $190.37 $658 - $761
4 New
4 $0

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Simon Quick Advisors, LLC Portfolio

Follow Simon Quick Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simon Quick Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simon Quick Advisors, LLC with notifications on news.